Acarix (Q1 Initial take): Topline in line, but improved cost base - Redeye

Redeye provides its initial take on Acarix’s Q1 report, which saw sales in line with estimates but a materially better cost base than we had anticipated. As such, we have a positive view of the report and expect a positive share price reaction during the day.

Länk till analysen i sin helhet: https://www.redeye.se/research/1167372/acarix-q1-initial-take-topline-in-line-but-improved-cost-base?utm_source=finwire&utm_medium=RSS